Clinical Policy: Use of Intravenous Tissue Plasminogen Activator for the Management of Acute Ischemic Stroke in the Emergency Department from the

Annals of Emergency Medicine

Volumn 66, Issue 3, 2015, Pages 322-333.e31

  Brown, Michael D ^a   Burton, John H ^a   Nazarian, Devorah J ^a   Promes, Susan B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR; FIBRINOLYTIC AGENT;

ARTICLE; BRAIN ISCHEMIA; DRUG EFFICACY; DRUG SAFETY; DRUG USE; EMERGENCY WARD; HEALTH CARE POLICY; HUMAN; META ANALYSIS; PATIENT CARE; PRIORITY JOURNAL; SYSTEMATIC REVIEW; EMERGENCY HEALTH SERVICE; INTRAVENOUS DRUG ADMINISTRATION; PRACTICE GUIDELINE; STROKE; TIME;

EMERGENCY SERVICE, HOSPITAL; FIBRINOLYTIC AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; STROKE; TIME; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84940052787     PISSN: 01960644     EISSN: 10976760     Source Type: Journal    
DOI: 10.1016/j.annemergmed.2015.06.031     Document Type: Review

References (100)

1. J.A. Edlow, E.E. Smith, L.G. Stead, et al. American College of Emergency Physicians and American Academy of Neurology Clinical policy: use of intravenous tPA for the management of acute ischemic stroke in the emergency department Ann Emerg Med 61 2013 225 243
2. A.S. Go, D. Mozaffarian, V.L. Roger, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics - 2014 update: a report from the American Heart Association Circulation 129 2014 e28 e292
3. K.D. Kochanek, J. Xu, S.L. Murphy, and et al. Deaths: final data for 2009 Natl Vital Stat Rep 60 2011 1 116
4. D.H. Newman, and J.D. Schuur Streetlights and quality measures for stroke Ann Emerg Med 64 2014 245 247
5. E.C. Jauch, J.L. Saver, H.P. Adams Jr., et al. American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Peripheral Vascular Disease, and Council on Clinical Cardiology Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association Stroke 44 2013 870 947
6. th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2012 e601S e636S
7. J.L. Banks, and C.A. Marotta Outcomes validity and reliability of the modified Rankin Scale: implications for stroke clinical trials: a literature review and synthesis Stroke 38 2007 1091 1096
8. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke N Engl J Med 333 1995 1581 1587
9. C. Gumbinger, P. Gruschka, M. Bottinger, and et al. Improved prediction of poor outcome after thrombolysis using conservative definitions of symptomatic hemorrhage Stroke 43 2012 240 242
10. J.R. Hoffman, and D.L. Schriger A graphic reanalysis of the NINDS trial Ann Emerg Med 54 2009 329 336
11. PRISMS trial. ClinicalTrials.gov: NCT02072226. Available at: https://clinicaltrials.gov/ct2/show/NCT02072226. Accessed November 7, 2014.
12. D.A. Christakis, and F.J. Zimmerman Rethinking reanalysis JAMA 310 2013 2499 2500
13. W. Feng, G. Vasquez, F.K. Suri, and et al. Repeated-measures analysis of the National Institute of Neurological Disorders and Stroke rt-PA stroke trial J Stroke Cerebrovasc Dis 20 2011 241 246
14. J.R. Marler, B.C. Tilley, M. Lu, and et al. Early stroke treatment associated with better outcome. The NINDS rt-PA stroke study Neurology 55 2000 1649 1655
15. J.L. Saver, J. Gornbein, and S. Starkman Graphic reanalysis of the two NINDS-tPA trials confirms substantial treatment benefit Stroke 41 2010 2381 2390
16. K.C. Johnston, A.F. Connors Jr., D.P. Wagner, and et al. Risk adjustment effect on stroke clinical trials Stroke 35 2004 e43 e45
17. J.L. Saver, and B. Yafeh Confirmation of tPA treatment effect by baseline severity-adjusted end point reanalysis of the NINDS-tPA stroke trials Stroke 38 2007 414 416
18. T. Kwiatkowski, R. Libman, B.C. Tilley, and et al. The impact of imbalances in baseline stroke severity on outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Ann Emerg Med 45 2005 377 384
19. T.J. Ingall, W.M. O'Fallon, K. Asplund, and et al. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial Stroke 35 2004 2418 2424
20. M. Mazighi, S.A. Chaudhry, M. Ribo, and et al. Impact of onset-to-reperfusion time on stroke mortality: a collaborative pooled analysis Circulation 127 2013 1980 1985
21. W. Hacke, M. Kaste, E. Bluhmki, et al. ECASS Investigators Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke N Engl J Med 359 2008 1317 1329
22. W. Hacke, M. Kaste, C. Fieschi, and et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) Lancet 352 1998 1245 1251
23. P. Sandercock, J.M. Wardlaw, R.I. Lindley, et al. for the IST-3 Collaborative Group The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third International Stroke Trial [IST-3]): a randomised controlled trial Lancet 379 2012 2352 2363
24. J.M. Wardlaw, V. Murray, E. Berge, and et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis Lancet 379 2012 2364 2372
25. J. Emberson, K.R. Lees, P. Lyden, et al. for the Stroke Thrombolysis Trialists' Collaborative Group Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials Lancet 384 2014 1929 1935
26. J. Aoki, K. Kimura, M. Koga, and et al. NIHSS-time score easily predicts outcomes in rt-PA patients: The SAMURAI rt-PA registry J Neurol Sci 327 2013 6 11
27. T. Hirano, M. Sasaki, N. Tomura, et al. Japan Alteplase Clinical Trial Group Low Alberta stroke program early computed tomography score within 3 hours of onset predicts subsequent symptomatic intracranial hemorrhage in patients treated with 0.6 mg/kg alteplase J Stroke Cerebrovasc Dis 21 2012 898 902
28. M. Karlinski, A. Kobayashi, R. Mikulik, and et al. Intravenous alteplase in ischemic stroke patients not fully adhering to the current drug license in Central and Eastern Europe Int J Stroke 7 2012 615 622
29. W. Lang, C.H. Stadler, Z. Poljakovic, and et al. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke Int J Stroke 8 2013 95 104
30. S. Abilleira, A. Davalos, A. Chamorro, and et al. Outcomes of intravenous thrombolysis after dissemination of the stroke code and designation of new referral hospitals in Catalonia: the Catalan Stroke Code and Thrombolysis (Cat-SCT) monitored study Stroke 42 2011 2001 2006
31. I. Antoncic, S. Dunatov, M. Bralic, and et al. Intravenous thrombolysis for acute ischemic stroke - our experiences Coll Antropol 35 2011 483 486
32. P. Bhatnagar, D. Sinha, R.A. Parker, and et al. Intravenous thrombolysis in acute ischaemic stroke: a systematic review and meta-analysis to aid decision making in patients over 80 years of age J Neurol Neurosurg Psychiatry 82 2011 712 717
33. X.L. Liao, C.X. Wang, Y.L. Wang, et al. Thrombolysis Implementation and Monitor of acute ischemic Stroke in China (TIMS-China) Investigators Implementation and outcome of thrombolysis with alteplase 3 to 4.5 h after acute stroke in Chinese patients CNS Neurosci Ther 19 2013 43 47
34. S.C. Martins, M.A. Friedrich, R. Brondani, and et al. Thrombolytic therapy for acute stroke in the elderly: an emergent condition in developing countries J Stroke Cerebrovasc Dis 20 2011 459 464
35. P.S. Sung, C.H. Chen, H.C. Hsieh, and et al. Outcome of acute ischemic stroke in very elderly patients: is intravenous thrombolysis beneficial? Eur Neurol 66 2011 110 116
36. T.H. Park, J.S. Lee, S.S. Park, and et al. Safety and efficacy of intravenous recombinant tissue plasminogen activator administered in the 3- to 4.5-hour window in Korea J Stroke Cerebrovasc Dis 23 2014 1805 1812
37. N. Ahmed, L. Kellert, K.R. Lees, and et al. Results of intravenous thrombolysis within 4.5 to 6 hours and updated results within 3 to 4.5 hours of onset of acute ischemic stroke recorded in the Safe Implementation of Treatment in Stroke International Stroke Thrombolysis Register (SITS-ISTR). An observational study JAMA Neurol 70 2013 837 844
38. S.F. Sung, S.C. Chen, H.J. Lin, and et al. Comparison of risk-scoring systems in predicting symptomatic intracerebral hemorrhage after intravenous thrombolysis Stroke 44 2013 1561 1566
39. M. Alias, I. Staff, and L.D. McCullough Early experience with community implementation of thrombolysis three to 4.5 hours after acute ischemic stroke Conn Med 75 2011 531 536
40. T.H. Chao, T.C. Lin, Y. Shieh, and et al. Intracerebral hemorrhage after thrombolytic therapy in acute ischemic stroke patients with renal dysfunction Eur Neurol 70 2013 316 321
41. C.A. Cronin, K.N. Sheth, X. Zhao, and et al. Adherence to third European Cooperative Acute Stroke Study 3- to 4.5-hour exclusions and association with outcome: data from Get With the Guidelines - Stroke Stroke 45 2014 2745 2749
42. A.C. Flint, R. Gupta, W.S. Smith, et al. SITS International and VISTA-plus investigators The THRIVE score predicts symptomatic intracerebral hemorrhage after intravenous tPA administration in SITS-MOST Int J Stroke 9 2014 705 710
43. M. Mehrpour, M. Aghaei, and M.R. Motamed Safety and feasibility of intravenous thrombolytic therapy in Iranian patients with acute ischemic stroke Med J Islam Repub Iran 27 2013 113 118
44. J.L. Saver, G.C. Fonarow, E.E. Smith, and et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke JAMA 309 2013 2480 2488
45. M. Chowdhury, J. Birns, A. Rudd, and et al. Telemedicine versus face-to-face evaluation in the delivery of thrombolysis for acute ischaemic stroke: a single centre experience Postgrad Med J 88 2012 134 137
46. J.T. Saarinen, N. Sillanpaa, H. Rusanen, and et al. The mid-M1 segment of the middle cerebral artery is a cutoff clot location for good outcome in intravenous thrombolysis Eur J Neurol 19 2012 1121 1127
47. S. Kono, K. Deguchi, N. Morimoto, and et al. Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan J Stroke Cerebrovasc Dis 22 2013 190 196
48. R.C. Seet, Y. Zhang, E.F. Wijdicks, and et al. Thrombolysis outcomes among obese and overweight stroke patients: an age- and National Institutes of Health Stroke Scale-matched comparison J Stroke Cerebrovasc Dis 23 2014 1 6
49. J.S. McKinney, J. Masjuan, F. Purroy, and et al. Safety of thrombolytic therapy for acute ischemic stroke after recent transient ischemic attack J Stroke Cerebrovasc Dis 21 2012 551 554
50. J.M. Wardlaw, V. Murray, E. Berge, and et al. Thrombolysis for acute ischaemic stroke (review) Cochrane Database Syst Rev 7 2014 CD000213
51. R. Topakian, M. Brainin, R. Eckhardt, and et al. Thrombolytic therapy for acute stroke in Austria: data from the Safe Implementation of Thrombolysis in Stroke (SITS) register Eur J Neurol 18 2011 306 311
52. W.M. Clark, S. Wissman, G.W. Albers, et al. ATLANTIS Study Investigators Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The Atlantis Study: a randomized controlled trial JAMA 282 1999 2019 2026
53. M. Ebinger, J.F. Scheitz, A. Kufner, and et al. MRI-based intravenous thrombolysis in stroke patients with unknown time of symptom onset Eur J Neurol 19 2012 348 350
54. P. Garcia-Bermejo, A.I. Calleja, S. Perez-Fernandez, and et al. Perfusion computed tomography-guided intravenous thrombolysis for acute ischemic stroke beyond 4.5 hours: a case-control study Cerebrovasc Dis 34 2012 31 37
55. P.R. Paliwal, A. Ahmad, L. Shen, and et al. Persistence of hyperdense middle cerebral artery sign on follow-up CT scan after intravenous thrombolysis is associated with poor outcome Cerebrovasc Dis 33 2012 446 452
56. T. Sairanen, S. Soinila, M. Nikkanen, and et al. Two years of Finnish telestroke: thrombolysis at spokes equal to that at the hub Neurology 76 2011 1145 1152
57. P. Sobolewski, M. Sledzinska-Dzwigal, W. Szczuchniak, and et al. The efficacy and safety of intravenous thrombolysis with alteplase in the treatment of ischaemic stroke in a rural hospital Neurol Neurochir Pol 47 2013 310 318
58. D. Strbian, P. Ringleb, P. Michel, and et al. Ultra-early intravenous stroke thrombolysis. Do all patients benefit similarly? Stroke 44 2013 2913 2916
59. G. Turc, M. Apoil, O. Naggara, and et al. Magnetic resonance imaging-DRAGON score: 3-month outcome prediction after intravenous thrombolysis for anterior circulation stroke Stroke 44 2013 1323 1328
60. Z. Vujkovic, D. Racic, S. Miljkovic, and et al. Hemorrhagic complications of thrombolytic therapy Med Pregl 65 2012 9 12
61. Y. Xian, L. Liang, E.E. Smith, and et al. Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator JAMA 307 2012 2600 2608
62. S.M. Zinkstok, Y.B. Roos ARTIS Investigators Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial Lancet 380 2012 731 737
63. P.A. Dharmasaroja, P. Dharmasaroja, and S. Muengtaweepongsa Outcomes of Thai patients with acute ischemic stroke after intravenous thrombolysis J Neurol Sci 300 2011 74 77
64. U. Fischer, M.L. Mono, M. Zwahlen, and et al. Impact of thrombolysis on stroke outcome at 12 months in a population: the Bern stroke project Stroke 43 2012 1039 1045
65. M. Al-Khaled, C. Matthis, and J. Eggers Predictors of in-hospital mortality and the risk of symptomatic intracerebral hemorrhage after thrombolytic therapy with recombinant tissue plasminogen activator in acute ischemic stroke J Stroke Cerebrovasc Dis 23 2014 7 11
66. X. Tong, M.G. George, Q. Yang, and et al. Predictors of in-hospital death and symptomatic intracranial hemorrhage in patients with acute ischemic stroke treated with thrombolytic therapy: Paul Coverdell Acute Stroke Registry 2008-2012 Int J Stroke 9 2014 728 734
67. L.L. Yeo, P. Paliwal, H.L. Teoh, and et al. Early and continuous neurologic improvements after intravenous thrombolysis are strong predictors of favorable long-term outcomes in acute ischemic stroke J Stroke Cerebrovasc Dis 22 2013 e590 e596
68. P.A. Dharmasaroja, S. Muengtaweepongsa, J. Pattaraarchachai, and et al. Intracerebral hemorrhage following intravenous thrombolysis in Thai patients with acute ischemic stroke J Clin Neurosci 19 2012 799 803
69. W.J. Meurer, H. Kwok, L.E. Skolarus, and et al. Does preexisting antiplatelet treatment influence postthrombolysis intracranial hemorrhage in community-treated ischemic stroke patients? An observational study Acad Emerg Med 20 2013 146 154
70. M. Paciaroni, G. Agnelli, V. Caso, and et al. Intravenous thrombolysis for acute ischemic stroke associated to extracranial internal carotid artery occlusion: the ICARO-2 study Cerebrovasc Dis 34 2012 430 435
71. S.R. Messe, G.C. Fonarow, E.E. Smith, and et al. Use of tissue-type plasminogen activator before and after publication of the European Cooperative Acute Stroke Study III in Get With the Guidelines - Stroke Circ Cardiovasc Qual Outcomes 5 2012 321 326
72. E.H. Wong, A.Y. Lau, Y.O. Soo, and et al. Is stroke thrombolysis safe and efficacious in Hong Kong? Hong Kong Med J 18 2012 92 98
73. M. Ebinger, B. Winter, M. Wendt, and et al. Effect of the use of ambulance-based thrombolysis on time to thrombolysis in acute ischemic stroke. A randomized clinical trial JAMA 311 2014 1622 1631
74. G.C. Fonarow, X. Zhao, and E.E. Smith Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative JAMA 311 2014 1632 1640
75. C.Y. Hsieh, H.J. Lin, S.F. Sung, and et al. Is renal dysfunction associated with adverse stroke outcome after thrombolytic therapy? Cerebrovasc Dis 37 2014 51 56
76. M. Reiter, Y. Teuschi, K. Matz, and et al. Diabetes and thrombolysis for acute stroke: a clear benefit for diabetics Eur J Neurol 21 2014 5 10
77. D. Strbian, P. Michel, D.J. Seiffge, and et al. Symptomatic intracranial hemorrhage after stroke thrombolysis: comparison of prediction scores Stroke 45 2014 752 758
78. A. Ciccone, L. Valvassori, M. Nichelatti, et al. SYNTHESIS Expansion Investigators Endovascular treatment for acute ischemic stroke N Engl J Med 368 2013 904 913
79. V. Matijevic, Z. Poljakovic, B. Malojcic, and et al. Systemic thrombolytic therapy in acute ischemic stroke - new experiences in spreading network of stroke units in Croatia J Neurol Sci 314 2012 126 129
80. S. Lahoti, S. Gokhale, L. Caplan, and et al. Thrombolysis in ischemic stroke without arterial occlusion at presentation Stroke 45 2014 2722 2727
81. M.J. Lyerly, K.C. Albright, A.K. Boehme, and et al. Safety of protocol violations in acute stroke tPA administration J Stroke Cerebrovasc Dis 23 2014 855 860
82. K. Murao, D. Leys, A. Jacquin, et al. OPHELIE-COG Investigators Thrombolytic therapy for stroke in patients with preexisting cognitive impairment Neurology 82 2014 2048 2054
83. M. Goyal, A.M. Demchuk, B.K. Menon, et al. ESCAPE Trial Investigators Randomized assessment of rapid endovascular treatment of ischemic stroke N Engl J Med 372 2015 1019 1030
84. B.C. Campbell, P.J. Mitchell, T.J. Kleinig, et al. EXTEND-IA Investigators Endovascular therapy for ischemic stroke with perfusion-imaging selection N Engl J Med 372 2015 1009 1018
85. D.M. Kent, P.M. Rothwell, J.P. Ioannidis, and et al. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal Trials 11 2010 85
86. D.M. Kent, and R.A. Hayward Limitations of applying summary results of clinical trials to individual patients. The need for risk stratification JAMA 298 2007 1209 1212
87. D.M. Kent, H.P. Selker, R. Ruthazer, and et al. The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke Stroke 37 2006 2957 2962
88. R.G. Gonzalez, M.H. Lev, G.V. Goldmacher, and et al. Improved outcome prediction using CT angiography in addition to standard ischemic stroke assessment: results from the STOPStroke study PLoS One 7 2012 e30352
89. B.K. Menon, J.L. Saver, S. Prabhakaran, and et al. Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator Stroke 43 2012 2293 2299
90. A.C. Chao, C.K. Liu, C.H. Chen, et al. Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) Study Group Different doses of recombinant tissue-type plasminogen activator for acute stroke in Chinese patients Stroke 45 2014 2359 2365
91. B. Singh, A.K. Parsaik, L.J. Prokop, and et al. Endovascular therapy for acute ischemic stroke: a systematic review and meta-analysis Mayo Clin Proc 88 2013 1056 1065
92. M.D. Hill, A.M. Demchuk, M. Goyal, and et al. Alberta Stroke Program early computed tomography score to select patients for endovascular treatment. Interventional Management of Stroke (IMS)-III Trial Stroke 45 2014 444 449
93. O.A. Berkhemer, P.S. Fransen, D. Beumer, et al. The MR CLEAN Investigators A randomized trial of intraarterial treatment for acute ischemic stroke N Engl J Med 372 2015 11 20
94. J.L. Saver, M. Goyal, A. Bonafe, et al. SWIFT PRIME Investigators Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke N Engl J Med 372 2015 2285 2295
95. D. Flynn, M.A. Knoedler, E.P. Hess, and et al. Engaging patients in health care decisions in the emergency department through shared decision-making: a systematic review Acad Emerg Med 19 2012 959 967
96. F. Legare, and H.O. Witteman Shared decision making: examining key elements and barriers to adoption into routine clinical practice Health Aff (Millwood) 32 2013 276 284
97. T.C. Hoffmann, V.M. Montori, and C. Del Mar The connection between evidence-based medicine and shared decision making JAMA 312 2014 1295 1296
98. T.C. Hoffmann, and C. Del Mar Patients' expectations of the benefits and harms of treatments, screening, and tests. A systematic review JAMA Intern Med 2014;Dec 22 E1 E13
99. D. Flynn, G.A. Ford, L. Stobbart, and et al. A review of decision support, risk communication and patient information tools for thrombolytic treatment in acute stroke: lessons for tool developers BMC Health Serv Res 13 2013 1 13
100. J. Gadhia, S. Starkman, B. Ovbiagele, and et al. Assessment and improvement of figures to visually convey benefit and risk of stroke thrombolysis Stroke 41 2010 300 306